FDA Approved: NABUMETONE — Original Application (ScieGen Pharmaceuticals Inc)

View source ↗

Summary

FDA approves ScieGen Pharmaceuticals Inc's Nabumetone as a generic product under an Original Application (ANDA), marking its regulatory approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Rheumatoid Arthritis

Drugs mentioned

• Nabumetone (Nabumetone)

Snippet

ORIG AP for NABUMETONE (NABUMETONE)